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INTRODUCTION
Previous randomized studies have demonstrated that coro-
nary artery bypass grafting (CABG) was associated with fewer
episodes of angina, less requirement for repeated revascular-
ization, but similar rates of death or myocardial infarction
(MI) compared with percutaneous coronary intervention (PCI)
(1-7). The Bypass Angioplasty Revascularization Investiga-
tion (BARI) study reported a better long-term survival rate
in the CABG group for diabetic patients (8). However, those
studies were performed in the pre-stent era and are therefore
not representative of currently available technologies. The use
of stents for percutaneous coronary artery intervention decreas-
es acute complications, late restenosis, and the requirement
for repeated revascularization (9, 10). Recently, an Argentinian
randomized study showed that percutaneous coronary stent
implantation was superior to CABG in terms of both survival
and MI (11). However, recent American and European trials
reported that CABG was associated with a similar survival
rate and stroke- or MI-free survival as PCI (12, 13). Many
studies are underway to clarify this issue. In Asia, however,
studies comparing CABG and PCI are rare.
The Korean Multicenter Revascularization Registry (KORR)
is a retrospective registry with physician-guided selection of
treatment. This study was designed to assess the relative mer-
its of PCI versus CABG in the post-stent era in multivessel
coronary artery disease (MVCAD), particularly for diabetic
patients.
MATERIALS AND METHODS
Study design
This study is in compliance with human studies commit-
tees in our hospital and Food and Drug Administration guide-
lines. For the study was designed as a retrospective registry
of PCI and CABG, the distribution of baseline characteristics
was not comparable between the two groups. We adjusted
the distribution of several risk factors that were found to be
important for clinical events, as described below.
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Percutaneous Coronary Intervention versus Coronary Artery Bypass
Grafting for Diabetics with Multivessel Coronary Artery Disease: 
The Korean Multicenter Revascularization Registry (KORR) 
This study was designed to assess the relative merits of percutaneous coronary
intervention (PCI) and coronary artery bypass grafting (CABG) in multivessel coro-
nary artery disease (MVCAD), particularly for Korean diabetics. Among 3,279 patients
with MVCAD who were recommended for revascularization were enrolled from nine
centers in Korea, 2,154 were selected after statistical adjustments for the disparities
between two groups. Survival rates were not significantly different for three years
between two groups. Among diabetic patients, the three-year mortality rate in PCI
group was 1.9-fold higher than that of CABG group, although it was not statistically
significant (PCI 19.8%, CABG 11.4%, p=0.14). The three-year mortality rate was
similar between the two groups in non-diabetics (PCI 8.3%, CABG 10.0%, p=0.50).
The 30-day rate of cerebrovascular event was higher in CABG group, for both dia-
betic (CABG 3.6%, PCI 0.0%, p<0.001) and non-diabetic patients (CABG 2.4%, PCI
0.0%, p<0.001). Short- and long-term revascularization rates were higher in PCI
group than in CABG group. As a conclusion, this Korean registry demonstrates that
PCI was associated with comparable survival rates and lower short-term morbidity,
but a greater requirement for repeated revascularization compared with CABG in
Korean diabetics.
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Screening process
Patients with two- or three-vessel coronary artery disease
who underwent elective PCI or CABG between January 1995
and December 2000 in one of nine centers in Korea were
enrolled in this registry. Patients with stable angina, acute
coronary syndrome (ACS), acute myocardial infarction (AMI),
or silent myocardial ischemia were included. Patients with
cardiogenic shock, AMI indicated for primary PCI, concomi-
tant valve surgery, a history of CABG, or mechanical compli-
cations such as ventricular septal defect, myocardial free-wall
rupture, or mitral regurgitation, were excluded. Patients with
significant left main disease were also excluded, to reduce the
disparity in disease severity between the CABG and PCI gro-
ups. A total of 3,279 patients were included: 1,182 treated
with CABG and 2,097 with PCI. 
CABG and PCI techniques
CABG was performed with standard surgical techniques.
Complete revascularization was attempted whenever possible,
using arterial conduit or saphenous vein grafts. PCI was also
performed using standard techniques. Patients were treated
with aspirin (100-300 mg daily) 24 hr before the procedure.
Ticlopidine (500 mg daily) or cilostazol (500 mg daily) was
given when stent implantation was planned, and continued
for at least two weeks after stent implantation. Intravenous
heparin was used to maintain an activated clotting time of
more than 300 sec during the procedure. The use of abciximab
was limited to 0.8%. Stents were used for either bail-out or
elective procedures.
Adjustment of disparities in the distribution of prognostic
factors 
Compared to CABG group, PCI group showed significantly
higher proportion of patients with old age (age≥65 yr), clin-
ical diagnosis of AMI, normal left ventricular function. The
clinical diagnosis of ACS, treated diabetes (diabetes currently
treated with oral hypoglycemic drugs or insulin), and history
of smoking, previous PCI, and previous cerebrovascular event
(CVE) history were significantly less frequent in PCI group,
respectively. Coronary angiogram showed significantly lower
proportion of 3-vessel disease and proximal LAD lesion in
PCI group, too. Risk factors for major adverse cardiac events
(MACE) with the corresponding odds ratios are listed in Table
1. MACE was defined as death, myocardial infarction (MI),
revascularization, or CVE.
Statistical adjustments were required to control for dispar-
ities in the distribution of independent prognostic factors
between the PCI and CABG groups. Matched variables in-
3 yr MACE
OR p-value
1 yr MACE
OR p-value
30 day MACE
OR p-value
PCI 1.18 0.52 3.48 <0.001 4.39 <0.001
Female 1.49 0.14 0.99 0.95 1.17 0.28
Age≥65 yr 1.65 0.024 1.32 0.010 1.46 0.002
ACS 1.42 0.18 1.36 0.009 1.35 0.018
AMI 2.34 0.008 1.44 0.021 1.34 0.093
Three-vessel disease 1.23 0.36 1.06 0.62 1.03 0.82
Treated diabetes (%) 1.34 0.21 1.13 0.32 1.58 0.001
Smoking 1.73 0.035 0.90 0.38 1.11 0.42
LVEF≥50% (%) 0.65 0.071 0.75 0.020 0.67 0.005
CVE history 2.54 0.001 1.53 0.011 1.59 0.014
MI history 1.59 0.071 1.06 0.69 1.99 0.92
Proximal LAD 1.28 0.27 1.44 0.001 1.42 0.003
Table 1. Risk factors and odds ratios for MACE for the total pop-
ulation by multivariate logistic regression analysis. PCI, old age,
diagnosis of ACS or AMI, the presence of treated diabetes, LVEF
≥50%, CVE history, and significant proximal LAD lesion were
associated with a higher risk of MACE
MACE, major adverse cardiovascular event; OR, odds ratio; PCI, per-
cutaneous coronary intervention; ACS, acute coronary syndrome; AMI,
acute myocardial infarction; LVEF, left ventricular ejection fraction; CVE,
cerebrovascular event; MI, myocardial infarction; proximal LAD, signifi-
cant lesion in the proximal left anterior descending artery.
Non-DM group
CABG PCI p-value
DM group
CABG PCI p-value
Female sex (%) 23.9 27.1 0.186 35.8 35.6 0.961
Age≥65 yr (%)* 37.2 35.9 0.633 35.3 37.8 0.558
Age (yr) 60.8± 61.0± 0.787 61.9± 62.2± 0.650
0.4 0.3 0.6 0.5
ACS (%)* 56.1 53.4 0.324 56.7 52.1 0.287
AMI (%)* 9.6 9.1 0.787 9.3 8.5 0.453
Hypertension (%) 54.1 56.2 0.459 62.2 56.7 0.205
Smoking (%) 56.5 42.8 <0.001 48.8 34.7 0.001
FHx of CAD (%) 10.6 6.5 0.006 6.5 5.8 0.27
LVEF (%) 55.1± 57.7± 0.015 54.5± 53.5± 0.456
0.5 0.4 0.9 0.8
LVEF≥50% (%)* 78.3 77.4 0.707 69.7 69.6 0.988
PCI history (%) 17.2 11.7 0.004 15.4 11.0 0.125
CVE history (%)* 8.7 8.6 0.951 11.4 13.4 0.498
MI history (%) 24.6 16.4 <0.001 25.9 15.6 0.003
PVD history (%) 5.9 4.3 0.168 7.5 6.3 0.603
Three-vessel 67.2 29.9 <0.001 72.6 32.9 <0.001
disease (%)
Lesion number 4.0± 3.0± <0.001 4.2± 3.2±<0.001
0.1 0.0 0.1 0.1
Proximal LAD (%)* 44.1 42.6 0.587 39.8 42.7 0.497
LAD intervention (%) 96.1 51.8 <0.001 96.5 53.2 <0.001
Table 2. Clinical and angiographic characteristics of patients
after matching six variables (marked as*). The numbers of patients
with risk factors are similarly adjusted in the CABG and PCI gro-
ups after the matching process
*Variables for which adjustments were made. CABG, coronary artery
bypass graft surgery; PCI, percutaneous coronary intervention; DM, treat-
ed diabetes; ACS, acute coronary syndrome; AMI, acute myocardial
infarction; FHx of CAD, family history of coronary artery disease; LVEF,
left ventricular ejection fraction; CVE, cerebrovascular event; MI, myocar-
dial infarction; PVD, peripheral vascular disease; proximal LAD, signifi-
cant lesion in the proximal left anterior descending artery.198 H.-C. Gwon, S.H. Choi, B.-I. Choi, et al.
cluded old age (age≥65 yr), clinical diagnosis (ACS or AMI),
normal left ventricular function, CVE history, and the pres-
ence of a significant lesion in the proximal left anterior des-
cending artery. The presence of diabetes was not matched
because we intended to evaluate the impact of diabetes on
clinical outcome, according to the two treatment modali-
ties. A total of 2,154 patients were selected for the statisti-
cally adjusted population. The clinical and angiographic
characteristics of the selected patients are listed in Table 2.
CABG and PCI groups were compared for the matched
population.
Statistical analysis
Results are presented as means±standard errors of the
means. A  2 test was used to determine the significant dif-
ferences in categorical variables. For comparison of continuous
variables, an unpaired t-test was used. For continuous variables
with a distribution other than a normal distribution, a Wil-
coxon two-sample test was used. Multivariate logistic regres-
sion analysis was performed to identify independent prog-
nostic factors. A log-rank test was used for the comparison
of Kaplan-Meier survival curves between groups. All tests
were two-tailed, and a p-value ≤0.05 was considered to be
statistically significant. 
RESULTS
Overall results
The average follow-up period was 2.1±1.6 yr (range, 0-6.6
yr). Eighty-four per cent of patients were followed-up for more
than one year, and 47.1% for more than three years.
There was no significant difference between the short- and
long-term mortality rates in the PCI and CABG groups up
to three years. The long-term incidence of morbidity (death,
MI, or CVE) was also not significantly different between gro-
ups, but the 30-day incidence was significantly higher in the
CABG group (CABG 4.0%, PCI 1.3%, p=0.001), which
was mainly due to a higher incidence of CVE in the CABG
group (CABG 2.8%, PCI 0.1%, p<0.001; Table 3, Fig. 1).
However, the incidence of MACE (death, MI, CVE, or revas-
cularization) was significantly higher in the PCI group than
in CABG group after one year, which was due to a higher
incidence of revascularization in the PCI group.
Influence of diabetes on clinical outcome
Of the matched population, 693 patients (32.2%) had a his-
tory of diabetes and 566 patients (26.3%) were being treated
with oral hypoglycemics or insulin (treated diabetic patients)
at the time of revascularization. In non-treated diabetics, 83.7
% of patients were followed-up for more than a year, and 47.9
% for more than 3 yr, and in treated diabetics, 83.0% for more
than a year and 44.9% for more than 3 yr.
Mortality rates were similar between the CABG and PCI
groups, for both the treated and non-treated diabetic patients
(Table 4, Fig. 2). In treated diabetic patients, the 30-day mor-
tality rate was 2.22-fold higher, whereas the three-year mor-
tality rate was 1.92-fold lower in the CABG group, although
these differences were not statistically significant. In none-
treated diabetic patients, however, the odds ratio was virtu-
ally not changed over three years. Treated diabetes was asso-
ciated with higher three-year mortality only in the PCI group
(non-treated diabetes 8.3%, treated diabetes 19.8%, odds
ratio=2.74, p=0.002).
The 30-day incidence of morbidity (death, MI, or CVE)
in the CABG group was significantly higher than in the PCI
group, for both non-treated and treated diabetics (non-treat-
ed diabetics: CABG 3.3%, PCI 1.0%, p=0.002; treated dia-
betics: CABG 5.6%, PCI 2.0%, p=0.026), mainly due to a
higher incidence of CVE in the CABG group. The 30-day
incidence of CVE was significantly higher in both non-treat-
ed and treated diabetics (non-treated diabetics: CABG 2.4%,
PCI 0.1%, p<0.001; treated diabetics: CABG 3.6%, PCI
0.0%, p<0.001).
CABG was preferable to PCI in terms of the risk of revas-
cularization, for both non-treated and treated diabetic patients.
Treated diabetes was a significant prognostic factor for three-
year revascularization (non-treated diabetes 46.9%, treated
CABG
(N=661)
PCI
(N=1,493)
p-value
Death (%) 30 day 1.4 0.8 0.20
1 yr 3.8 3.0 0.37
2 yr 6.5 5.3 0.40
3 yr 10.4 10.7 0.92
Death, MI, CVE (%) 30 day 4.0 1.3 <0.001
1 yr 7.8 5.8 0.13
2 yr 12.0 10.5 0.43
3 yr 18.8 18.9 0.97
MI (%) 30 day 0.2 0.2 0.78
CVE (%) 30 day 2.8 0.1 <0.001
Revascularization (%) 30 day 0.3 2.3 <0.001
1 yr 4.0 21.9 <0.001
2 yr 6.8 33.3 <0.001
3 yr 11.2 49.9 <0.001
MACE (%) 30 day 4.0 3.1 0.29
1 yr 10.5 24.3 <0.001
2 yr 16.8 37.0 <0.001
3 yr 25.6 53.9 <0.001
Table 3. Clinical event rate in the CABG and PCI groups. Survival
rate was similar between two groups. The 30-day incidence of
CVE was significantly higher in the CABG group. Long-term risk
of MACE was higher after PCI, mainly due to the higher risk of
revascularization
CABG, coronary artery bypass graft surgery; PCI, percutaneous coro-
nary intervention; MI, myocardial infarction; CVE, cerebrovascular event;
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diabetes 60.5%, odds ratio=1.29, p=0.003) and three-year
MACE rate only in the PCI group (non-treated diabetes 50.9
%, treated diabetes 62.2%, odds ratio=1.26, p=0.002). How-
ever, in CABG group, treated diabetes was not a significant
risk factor for any event.
MACE in diabetic subgroups within and between treatment
cohorts
None of the mortality, morbidity, or MACE rates differed
significantly among the four diabetes treatment modality
groups, either in the CABG or PCI groups (Fig. 3). Insulin-
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Fig. 1. Kaplan-Meier curve for cardiovascular event (CVE). Survival rates are similar for the two revascularization strategies. Long-term mor-
bidity (death, MI, or CVE) also dose not differ significantly, but the 30-day incidence of morbidity is significantly higher in the CABG group,
mainly due to a higher incidence of CVE in that group. The infarct- or CVE-free survival rate without revascularization is much higher in the
CABG group, due mainly to a lower revascularization rate.
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Fig. 2. Clinical outcomes according to diabetic status and revascularization strategy. Mortality and morbidity are similar after CABG or
PCI, both for treated diabetic and non-treated diabetic patients. For treated diabetic patients, however, the 30-day mortality rate is higher,
whereas the three-year mortality rate is lower in the CABG group, although these differences are not statistically significant. The 30-day
MI- or CVE-free survival rate is significantly higher in the CABG group due to the higher rate of CVE. MACE is significantly lower in the
CABG group.
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Fig. 3. Neither the mortality, morbidity, nor
MACE rate is significantly different bet-
ween the four diabetes treatment modality
groups, in either the CABG or PCI groups.
In the PCI group, treated diabetic patients
had a higher risk of MACE.
p=0.51 p=0.18
p=0.038
1.0
0.9
0.8
0.7
0.6
0.5
0123
PCI group (yr)
Non-diabetic
Diet only
Oral hypoglycemic
Insulin200 H.-C. Gwon, S.H. Choi, B.-I. Choi, et al.
treated diabetic patients, however, had a higher risk of MACE
than non-diabetic patients in the PCI group (p=0.038).
Arterial graft vs. stent
Stents were used in 68.5% of PCIs. Stent implantation was
associated with reduced 1-yr death or MI risk (non-stent 7.1
%, stent 3.6%, p=0.014) and reduced 30-day revasculariza-
tion rate (non-stent 3.6%, stent 1.6%, p=0.02). Arterial graft
was performed in 92.1% CABGs. The left internal mammary
artery was used in 91.1% of cases. In 14.2% of CABGs, only
arterial grafts were used. In 23.0% of CABGs, surgical pro-
cedures were performed without a cardiopulmonary bypass
pump. The arterial graft group showed a significantly lower
three-year mortality rate (arterial graft 8.6%, vein graft 21.6
%, p=0.016) and a lower three-year MACE rate (arterial graft
23.2%, vein graft 40.5%, p=0.017) compared with the vein-
graft-only group.
To compare current therapeutic technologies, the rate of
MACE was compared between the stent and arterial graft
groups. Thirty-day revascularization was reduced in the stent
group and did not differ significantly from that of the CABG-
with-arterial-graft group. Otherwise, the results were similar
to those of the total adjusted population.
DISCUSSION
This study is the first Korean multicenter registry that com-
pares the long-term clinical outcomes of two currently used
coronary revascularization strategies. Short- and long-term
mortality rates did not differ significantly between the PCI
and CABG groups after up to three years of follow-up. Early
morbidity was higher in the CABG group than in the PCI
group, due to a higher rate of CVE. Three-year event-free sur-
vival was much higher in the CABG group than in the PCI
group, due to an increased rate of revascularization in the PCI
group. 
Short- and long-term mortality rates did not differ signif-
icantly between the PCI and CABG groups for diabetic or
non-diabetic patients, although there was a trend in the PCI
group towards an increased three-year mortality rate among
diabetics. In the PCI group, diabetes was associated with sig-
nificantly higher mortality and MACE rates at three years,
in contrast to the CABG group in which the two cohorts did
not differ. In a separate analysis of arterial graft vs. stent, the
short- and long-term outcomes were similar to those of the
total adjusted population. 
Our current practice of selecting the treatment modality for
patients with MVCAD is based on the results of many prior
randomized trials (1-7). The BARI study is representative of
the pre-stent era. It demonstrated that CABG was more suc-
cessful than PCI in terms of the seven-year survival rate, mainly
due to the beneficial effects of CABG for diabetic patients.
The seven-year survival rate was 65.5% for PCI and 80.6%
for CABG in the diabetic group (p=0.003) (8). In non-dia-
betics, there was no difference in survival after PCI or CABG.
In the Emory Angioplasty versus Surgery Trial (EAST), treat-
ed diabetics showed similar mortality rates to non-treated dia-
betics until the three-year follow-up. However, the curves
began to diverge after five years, and by eight years, mortality
rates were better after surgery, although the differences were
not statistically significant (14). The Northern New England
Cardiovascular Disease Study also showed that diabetics treat-
p-value
Non-DM 
vs. DM
Non-DM group
CABG
p-
value
PCI OR
Non-DM group
CABG
p-
value
PCI CABG PCI OR
Death (%)
30D 0.9 0.7 0.75 0.64 2.5 1.2 0.45 0.23 0.0950.35
1Y 3.1 2.5 0.80 0.55 5.4 4.5 0.82 0.66 0.20 0.12
2Y 6.2 4.4 0.70 0.27 7.1 8.1 1.15 0.75 0.74 0.069
3Y 10.0 8.3 0.81 0.50 11.4 19.8 1.92 0.14 0.73 0.002
Death, MI, CVE(%)
30D 3.3 1.0 0.31 0.002 5.6 2.0 0.35 0.026 0.17 0.15
1Y 7.0 5.5 0.78 0.32 9.6 6.8 0.69 0.30 0.29 0.45
2Y 11.5 9.9 0.84 0.47 13.2 12.6 0.95 0.88 0.62 0.31
3Y 17.3 17.1 0.99 0.96 22.4 25.8 1.21 0.59 0.32 0.056
MI (%)
30D 0.2 0.2 0.86 0.90 0.0 0.3 - 0.45 0.51 0.71
CVE (%)
30D 2.4 0.1 0.04 <0.001 3.6 0.0 - <0.001 0.40 0.57
Revascularization (%)
30D 0.4 2.2 5.15 0.013 0.0 2.3 - 0.034 0.36 0.93
1Y 4.2 21.1 6.14 <0.001 3.7 24.6 3.61 <0.001 0.79 0.21
2Y 6.6 32.3 6.76 <0.001 7.2 36.6 7.45 <0.001 0.82 0.24
3Y 11.1 46.9 7.10 <0.001 11.5 60.5 11.6 <0.001 0.91 0.003
MACE (%)
30D 3.3 3.1 0.93 0.81 5.6 3.2 0.55 0.17 0.17 0.92
1Y 9.8 23.4 2.81 <0.001 12.2 27.2 2.68 <0.001 0.39 0.19
2Y 16.0 25.8 2.91 <0.001 18.5 40.9 3.04 <0.001 0.59 0.16
3Y 23.9 50.9 3.21 <0.001 29.3 64.2 4.32 <0.001 0.32 0.003
Table 4. Clinical outcomes in subgroups defined according to
treatment modality and the presence of treated diabetes. Mor-
tality rates were not significantly different after PCI or CABG for
three years, although mortality was 1.9-fold higher in the PCI
group compared with the CABG group. In non-diabetic patients,
the mortality rate was similar for the two revascularization strate-
gies for three years. Three-year mortality rates were significantly
higher for diabetics than for non-diabetics only in the PCI group.
The rate of death, MI or CVE after 30 days was higher in the
CABG group for diabetic and non-diabetic patients, as a result
of the higher 30-day CVE rate. Short- and long-term revascular-
ization was more frequent in the PCI group than in the CABG
group
CABG, coronary artery bypass graft surgery; PCI, percutaneous coro-
nary intervention; DM, treated diabetics; OR, odds ratio of the PCI group
compared with the CABG group; 30D, 30-day; 1Y, one-year; 2Y, two-year;
3Y, three-year; MI, myocardial infarction; CVE, cerebrovascular event;
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ed with PCI had mortality rates significantly higher than
patients undergoing CABG (hazard ratio=1.49, p=0.037)
(15). Mortality risk tended to increase more among patients
with three-vessel disease (hazard ratio=2.02, p=0.038) than
among patients with two-vessel disease (hazard ratio=1.33,
p=0.21).
In contrast, the BARI registry showed that seven-year sur-
vival was similar after PTCA or CABG (85.8% for PCI, 86.1
% for CABG, p=0.66) (16). Even among diabetics, PTCA and
CABG showed similar seven-year survival rates (74.0% for
PCI, 74.0% for CABG). The results of the Coronary Angio-
plasty versus Bypass Revascularization Investigation (CABRI)
trial also indicated that there was no significant difference
in four-year mortality rates between patients randomized to
either PCI or CABG strategies, in either diabetic or non-dia-
betic patients, although diabetes was a significant risk factor
for mortality (17). Duke University database also noted simi-
lar long-term outcomes after either PCI or CABG for diabetic
patients with multivessel disease (18).
Since the completion of these early major trials, significant
technological advances have been made in the field of coro-
nary revascularization, in both PCI and CABG. Stent implan-
tation is associated with greater clinical success, and a signifi-
cantly lower long-term revascularization rate (9, 10). Recent
PCI vs. CABG studies in the management of MVCAD have
utilized advanced technologies including stent implantation.
The Argentine randomized study (ERACI-II) also showed a
better survival rate with PCI than with CABG after 30 days
and at one year (11). However, the Arterial Revascularization
therapies Study (ARTS) and the Angina With Extremely Seri-
ous Operative Mortality Evaluation (AWESOME) study de-
monstrated similar mortality rates after 2-3 yr for PCI and
CABG (12, 13). Repeat revascularization rates seemed to
improve in the stent group compared with the rates for the
balloon groups of previous studies. However, rates of revas-
cularization were still significantly higher than those of the
CABG group, particularly for treated diabetics.
The prevalence of diabetes has been increasing explosively
in Korea, as in other eastern societies (19). This is also true
for mortality from coronary artery disease, which parallels
the prevalence of diabetes (20). Treatment for coronary artery
disease in diabetic patients is still not satisfactory in terms
of long-term mortality and morbidity. Despite many multi-
center trials, the most appropriate selection of a revasculariza-
tion strategy remains to be established, particularly in diabetic
patients with multivessel disease. Moreover, in Asian countries,
studies comparing long-term outcomes of PCI and CABG
in patients with advanced coronary artery disease are rare.
In Korea, Sim et al. reported similar early clinical outcome
and higher long-term target lesion revascularization rate in
the coronary stent group compared to coronary artery bypass
group in single center registry of 160 patients (30.5 months
follow-up: stent group 18.9%, bypass group 5.7%, p<0.005)
(21). This Korean registry study will increase our understand-
ing of the current situation and the outcomes associated with
revascularization procedures in this region of the world.
KORR showed similar short- and long-term mortality rates
for the two therapeutic modalities. These results are consis-
tent with most previous comparative studies on PCI vs. CABG
in the management of MVCAD. Similar survival rates were
observed for both diabetic and non-diabetic patients. This
finding is at variance with the BARI trial, but is similar to
the results of the ARTS (22) and BARI registry. In the ERACI
II study, the 30-day mortality rate was significantly higher
in the CABG group than in the PCI group, due to the high
mortality in the CABG group (PCI 0.9%, CABG 5.7%, p=
0.013), which is partly attributable to the high proportion
of patients with ACS in this study (11). In our data, however,
the 30-day mortality rate of patients with ACS was less than
2.0% in both revascularization groups (CABG 1.1%, PCI
0.3%, p=0.081).
Our data indicate that the early morbidity rate may be high-
er in the CABG group than in the PCI group. In the ARTS,
the risk of MI or CVE was similar in the two groups (13).
However, in KORR, the 30-day CVE risk was significantly
lower in the PCI group. The incidence of CVE in KORR was
lower than in the ARTS (KORR stent group, 30 days CVE,
0.0%, and one-year CVE, 0.6%; ARTS, one-year CVE, 1.5%).
The rate of CVE in this study was similar to that of the PCI
group in the ERACI II trial (30 days CVE, 0.0%) (11). Al-
though the repeat revascularization rate after PCI was higher
than after CABG, the rate difference between diabetics and
non-diabetics in KORR was less pronounced than in the
ARTS study.
When considering the relative merits of the two revascu-
larization techniques in the management of MVCAD in the
post-stent era, the two techniques seem equivalent in terms
of survival. However, CABG appears to be superior to PCI
insofar as the requirements for repeat revascularization is lower.
Treated diabetes was a risk factor for long-term mortality
only in the PCI group, but the relative advantages and dis-
advantages of CABG compared with PCI did not differ mar-
kedly between diabetic and non-diabetic patients in this study.
The survival benefit of CABG over PCI for diabetic patients
has been demonstrated only in studies with longer-term fol-
low-ups than that used in this study. The follow-up period
was less than three years in several recent studies, including
ERACI II, ARTS, and AWESOME. In the EAST trial, the
benefits of CABG for diabetics were demonstrated only after
five years. The survival curves for diabetic patients of this
study began to diverge after two years and showed a mortal-
ity rate in the PCI group almost twofold higher than that of
the CABG group, although the difference was not statistically
significant.
A common problem of long-term comparative studies of
PCI vs. CABG is that the results may become obsolete even
before publication, due to the speed of technological devel-
opment and advancement. Recently, drug-eluting stents have202 H.-C. Gwon, S.H. Choi, B.-I. Choi, et al.
shown very promising results on restenosis (23, 24). The res-
tenosis rate following stenting may be lowered further in the
future. Therefore, PCI with drug-coated stents may achieve
similar or even better outcomes than those of CABG, and
comparative assessments of drug-coated stent versus CABG
may be necessary in the near future.
One of the limitations of this study is that KORR is a ret-
rospective and non-randomized study with physician-guided
selection of treatment. Although the differences measured
between the two treatment groups were controlled, this sta-
tistical adjustment can be imperfect. Another important lim-
itation is that the long-term follow-up rate is relatively low
compared to previous western studies. Therefore, the two-
or three-year event rate may be even less reliable. The third
limitation is that the stent implantation rate was only 68.5%,
which is relatively low considering current practice of PCI
in Korea, because the patients of this study had been recruit-
ed before year 2001. Moreover, drug-eluting stents have been
already on the market for more than a year and dramatically
changed the revascularization strategy in the patients with
multi-vessel disease. The difficulty in keeping up the current
practice pattern always has been one of the major limitations
of large trials or registries with long term follow-up. The con-
temporary techniques should be considered to interpret and
apply this data to current practice in Korea.
As a conclusion, in this multicenter Korean registry, we
found that survival rates were similar after PCI and CABG
for treated diabetics as well as for the total population. Com-
pared with CABG, PCI was associated with a lower incidence
of short-term morbidity but with a greater requirement for
repeated revascularization, particularly in treated diabetics.
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